key: cord-0259281-d3ekk2dt authors: Ayoub, H. H.; Tomy, M.; Chemaitelly, H.; Altarawneh, H. N.; Coyle, P.; Tang, P.; Hasan, M. R.; Al Kanaani, Z.; Al Kuwari, E.; Butt, A. A.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Nasrallah, G.; Benslimane, F.; Al Khatib, H. A.; YASSINE, H. M.; Al Kuwari, M. G.; Al Romaihi, H. E.; Abdul-Rahim, H. F.; Al-Thani, M. H.; Al Khal, A.; Bertollini, R.; Abu-Raddad, L. J. title: Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design date: 2022-01-03 journal: nan DOI: 10.1101/2022.01.02.22268622 sha: 7113cc3e160397b7fd8178af37847a60cf69e3de doc_id: 259281 cord_uid: d3ekk2dt Background: The Coronavirus Disease 2019 (COVID-19) pandemic has highlighted an urgent need to use infection testing databases to rapidly estimate effectiveness of prior infection in preventing reinfection (PES) by novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: Mathematical modeling was used to demonstrate the applicability of the test-negative, case-control study design to derive PES. Modeling was also used to investigate effects of bias in PES estimation. The test-negative design was applied to national-level testing data in Qatar to estimate PES for SARS-CoV-2 infection and to validate this design. Results: Apart from the very early phase of an epidemic, the difference between the test-negative estimate for PES and the true value of PES was minimal and became negligible as the epidemic progressed. The test-negative design provided robust estimation of PES even when PES began to wane after prior infection. Assuming that only 25% of prior infections are documented, misclassification of prior infection status underestimated PES, but the underestimate was considerable only when >50% of the population was ever infected. Misclassification of latent infection, misclassification of current active infection, and scale-up of vaccination all resulted in negligible bias in estimated PES. PES against SARS-CoV-2 Alpha and Beta variants was estimated at 97.0% (95% CI: 93.6-98.6) and 85.5% (95% CI: 82.4-88.1), respectively. These estimates were validated using a cohort study design. Conclusions: The test-negative design offers a feasible, robust method to estimate protection from prior infection in preventing reinfection. Estimating effectiveness of prior infection in preventing reinfection ( S PE ) is essential to understand the epidemiology of a given infection. Various studies have estimated S PE for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, there are challenges in estimating S PE using conventional epidemiologic study designs. Such designs require extensive, complete electronic health records to be feasible. Vaccination scale-up makes it difficult to disentangle immunity induced by prior infection from that induced by vaccination. Even when it is feasible to apply conventional designs, estimates can be prone to strong bias, due to misclassification of prior infection status, since many prior infections are not documented. [10] [11] [12] [13] Effects of this bias increase with increased cumulative infection exposure in the population. 14 Recent emergence of the Omicron 15 (B.1.1.529) variant emphasized the need to estimate S PE immediately for this variant. Here, we demonstrate a robust, practical method to estimate S PE using a test-negative, casecontrol study design. This is, to our knowledge, the first use of this method to estimate S PE . While it has been used to study vaccine effectiveness, [16] [17] [18] [19] [20] [21] [22] [23] it does not appear to have been used to estimate S PE , perhaps because of a perception that it is not applicable, as most prior and current infections are undocumented, unlike vaccinations, which are typically documented and tracked in health systems. We also validate this method by actually estimating 6 infection in Qatar, at a time when the Alpha 15 (B.1.1.7) and Beta 15 (B.1.351) variants dominated incidence. [22] [23] [24] [25] [26] [27] Methods The test-negative, case-control study design has emerged as a robust and practical method to assess vaccine effectiveness for respiratory tract infections. [16] [17] [18] [19] [20] [21] [22] [23] In this design, persons seeking healthcare because of symptoms are recruited into the study. 16, 17 Those testing positive for the infection (cases) are then matched to those testing negative (controls). 16, 17 Matching is done to control for differences in the risk of exposure to the infection. 22, 23, 28 Vaccine effectiveness is then derived as one minus the ratio of the odds of vaccination in subjects testing positive to the odds of vaccination in subjects testing negative. 16, 17 A key strength of this design is removal of differences in healthcare-seeking behavior between vaccinated and unvaccinated persons, thereby minimizing bias. 16, 17 Another strength is minimization of bias arising from misclassification of infection. 16, 17 Mathematical modeling was used to demonstrate the applicability of the test-negative, casecontrol study design for deriving effectiveness of prior infection in preventing reinfection ( S PE ), that is, the proportional reduction in susceptibility to infection among those with prior infection versus those without. 2 Modeling was also used to investigate effects of biases on estimated S PE . While this demonstration was done for SARS-CoV-2 infection, the approach is generic and should be broadly applicable to a range of infections. 7 Several models were devised to simulate SARS-CoV-2 infection transmission in the population and to investigate applicability of the test-negative design. The models were informed by previously published models for SARS-CoV-2 infection. 10, 13, [29] [30] [31] [32] [33] [34] The first was the classic Susceptible Exposed Infectious Recovered (SEIR) model, but extended to allow for reinfections (Baseline Model; Figure 1A ). This model was used to demonstrate applicability of the testnegative design and to investigate sources of bias. The second was an extension of the Baseline Model to incorporate scale-up of vaccination in the population (Vaccination Model; Figure 1B The third was also an extension of the Baseline Model, incorporating gradual (linear) waning in protection offered by prior infection against reinfection (Waning of Immunity Model; Figure 1C ). These models consisted of coupled nonlinear differential equations that stratified the population into groups (compartments) based on infection status (infected, reinfected, or uninfected) and vaccination status (vaccinated, unvaccinated). Susceptible and recovered individuals (vaccinated All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint 8 or unvaccinated) were assumed at risk of acquiring the infection at a force of infection that varied throughout the epidemic due to variation in the contact rate. These models were calibrated to mimic the actual evolution of the COVID-19 epidemic in Qatar. 13, 29 The contact rate was varied to generate two major epidemic waves several months apart, as actually occurred. 13, 26, 29, 36 Parameters of the models are summarized in Table 1 . Further details on these models, their equations, and their parametrization can be found in previous publications. 10, 13, [29] [30] [31] [32] [33] [34] Modeling analyses were conducted in MATLAB R2019a (Boston/MA/USA). 37 Applying the test-negative, case-control study design, have been diagnosed. They may have been unaware of their infections. It is reasonable to assume that most persons with a prior infection may not have had it documented. [10] [11] [12] [13] Here, we assumed that 75% of prior infections are undocumented (Table 1 ). 9 Unlike vaccine effectiveness studies, in which records are typically available to track vaccinations, [16] [17] [18] [19] [20] [21] [22] [23] 28 most persons with prior infection could be misclassified as persons with no prior infection. Similarly, most currently active infections may not be documented. The 2-by-2 table is thus modified for this bias along with the expression for S PE ( Figure 2B ). It was assumed that this bias affects both cases and controls similarly, a valid assumption considering that both cases and controls are seeking healthcare because of symptoms. This assumption is central to the test-negative design strategy. 16, 17 A second source of bias is misclassification of latent infection status. A proportion E g of those with latent infections are asymptomatic; thereby remaining untested and undiagnosed. These cases would be misclassified as controls. The 2-by-2 table is thus modified to accommodate this bias along with the expression for S PE ( Figure 2C ). We assumed that 75% E g = (Table 1) . We also assumed that this bias similarly affects those with and without prior infection. This is a valid assumption considering that both are seeking healthcare for the same reason, another assumption central to the test-negative design strategy. 16, 17 A proportion I g of cases (current active infections) could be misclassified as controls, because of lack of testing or due to imperfect sensitivity of the testing method, thereby introducing another form of bias. The 2-by-2 table is thus modified for this bias along with the expression for S PE ( Figure 2D ). We assumed that 75% I g = (Table 1 ). We also assumed that this bias similarly affects those with and without prior infection. 16, 17 Estimation of S PE may occur at a time when vaccination is being scaled up, as in the current COVID-19 pandemic. This could introduce bias as vaccination is another form of immune All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint 10 protection. Using the Vaccination Model, the 2-by-2 table is modified in presence of vaccination along with the expression for S PE ( Figure 2E ). We assumed that vaccination is being linearly scaled up to reach the vaccine coverage attained in Qatar during the duration of the simulation. We also assumed that S PE is the same regardless of vaccination status; that is, hybrid immunity of prior infection and vaccination is superior to that of either prior infection or vaccination separately. 36, 38 Since different forms of bias may act synergistically when present together, the impact of the above biases was also investigated by applying all of them simultaneously. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. essentially only Beta and Alpha cases identified between March 8 and April 21, 2021, 22-27 a Beta case was proxied as the complement of the Alpha criterion, that is, any case with a Ct value ≤30 for the N, ORF1ab, and S genes. Only the first PCR-positive test during the study was included for each case, and only the first PCR-negative test during the study was included for each control, per established protocol for the test-negative design. 22, 23, 26, 28 Alpha and Beta cases were exact matched one-to-one to controls (PCR-negative persons) by sex, 10-year age group, nationality, and calendar week of PCR test. Matching of cases and controls was done to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar. 13, [43] [44] [45] [46] Further description of Qatar's databases and methods of analysis can be found in previous publications. 1-4, 22, 23, 26, 28, 36, 43 Socio-demographic characteristics of study samples were described using frequency distributions and measures of central tendency. The odds ratio, comparing odds of prior infection among cases versus controls, and its associated 95% confidence interval (CI) were derived using conditional logistic regression, factoring matching in the study design. This analytical approach is done to minimize potential bias due to variation in epidemic phase 16, 47 and other confounders. 13 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint Assuming that only 25% of prior infections are documented (Table 1 ), Figure 5A Figure S1 ). Applying the Waning of Immunity Model, Figure 4B shows (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint 13 prior infection against reinfection. This comparison was done after the second wave at day 600 after the virus introduction ( Figure 3A ). Qatar using the test-negative design. The median age of study subjects was 32-34 years, at least half were males, and they came from diverse countries ( Table 2 ). Study samples were broadly representative of Qatar's demographics. 43 Study results show that the test-negative design can be used to generate rigorous estimates for protection afforded by prior infection against reinfection, even though most prior infections are All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint 14 undocumented. Estimates were robust despite several forms of potential bias, and even under rather extreme assumptions for these biases. The test-negative design was also applied to Qatar's routine PCR testing data, and results were validated by comparing test-negative estimates to those generated using conventional cohort study designs. 4 Application of the test-negative design should be feasible in different countries as long as there are databases for infection testing that are of reasonable quality and that can be linked to documented prior infection status (and preferably to vaccination status). Such databases are available and have been used extensively in vaccine effectiveness studies, such as for SARS-CoV-2 infection. [18] [19] [20] [21] [22] [23] 28 Of the considered biases, only misclassification of prior infection status could have a large effect on S PE estimation, but mainly where more than 50% of the population already had a prior infection. This situation is unlikely to have been reached for SARS-CoV-2 infection in most countries. 52 Even in such situations, the direction (and magnitude) of bias is known; it underestimates S PE . Therefore, the test-negative design can still provide a lower bound for the true S PE , which may be sufficient to inform public health decision making. Thus, this bias may not restrict the utility of this method. The test-negative study design has strengths that conventional designs may lack. Cohort study designs can be affected by bias resulting from different infection testing frequencies in the two arms of the study. This bias does not affect the test-negative design, as it uses only those who are tested. An example can be seen in comparing the results of the test-negative design to the results of our earlier cohort design. 4 In the cohort design, adjustment for testing frequency reduced S PE from 97.6% (95% CI: 95.7-98.7%) to 95.8% (95% CI: 92.5-97.7%) for Alpha, 4 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. : 82.4-88.1) . Accordingly, the test-negative design may provide a more robust estimate than the cohort design. The test-negative design may also be preferable to the cohort design for other reasons. Cohort designs rely on cohorts that may not be strictly comparable, and it may not be possible to control for all differences in risk of exposure to the infection by matching and analysis adjustments. For example, in our earlier cohort study, 4 we compared those with a record of a prior PCR-confirmed infection to those with an antibody-negative test, but these two groups may differ in ways that cannot be controlled. Meanwhile, the test-negative design is perhaps less susceptible to such differences, as cases and controls are intentionally recruited for the same healthcare-seeking behavior. Lastly, while the test-negative design can be biased by misclassification of prior infection, the cohort design is perhaps more affected by this bias. The odds ratio metric in the test-negative design is less affected by this bias than the relative risk, incidence rate ratio, or hazard ratio metrics in the cohort design. In regard to limitations, specific forms of bias were investigated, but other sources of bias are possible, and these may depend on the database being analyzed. 26 There is already a volume of literature investigating other forms of bias for the test-negative design in the context of vaccine effectiveness estimation, 16 , 17 some of which may apply in the context of S PE estimation. While this study demonstrated use of the test-negative design to estimate S PE , other factors need to be considered in actual application. For instance, the algorithm for matching needs to be developed All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint 16 with knowledge of the local epidemiology to ensure that matching can effectively control differences in the risk of exposure to the infection. In conclusion, the test-negative design offers a feasible and robust method to estimate protection of prior infection in preventing reinfection. This method should be considered to provide rapid, rigorous estimates of protection offered by prior infection for different variants of SARS-CoV-2, such as the Omicron that emerged recently. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Proportion of prior infections that are undocumented p g 75% Informed by evidence from existing studies [10] [11] [12] [13] Proportion of latent infections that are undocumented E g 75% Informed by evidence from existing studies [10] [11] [12] [13] Proportion of current active infections that are undocumented I g 75% Informed by evidence from existing studies [10] [11] [12] [13] All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint Figure 6 . Flowchart describing the population selection process to estimate effectiveness of prior infection in preventing reinfection using the test-negative study design. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint Table 2 . Demographic characteristics of subjects in the samples used to estimate effectiveness of prior infection in preventing reinfection using the test-negative study design. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 3, 2022. ; https://doi.org/10.1101/2022.01.02.22268622 doi: medRxiv preprint Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study National Study Group for C-E. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers SARS-CoV-2 re-infection risk in Austria SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys Estimated US Infection-and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness Effectiveness of COVID-19 vaccines against variants of concern Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses Characterizing key attributes of COVID-19 transmission dynamics in China's original outbreak: Model-based estimations Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. Vaccines (Basel) 2020 Epidemiological Differences in the Impact of COVID-19 Vaccination in the United States and China Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar Protection and waning of natural and hybrid COVID-19 immunity. medRxiv 2021: 2021.12.04.21267114. 39. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use Characterizing the Qatar advancedphase SARS-CoV-2 epidemic SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112 Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness Analysis of matched case-control studies Modern epidemiology Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020 Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients United Nations Department of Economic and Social Affairs Population Dynamics. The 2019 Revision of World Population Prospects PCR, polymerase chain reaction SMD, standardized mean difference. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. † Nationalities were chosen to represent the most populous groups in Qatar ‡ These comprise 61 other nationalities in Qatar in the Alpha variant analysis and 78 other nationalities in the Beta variant analysis § SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching. ¶ SMD is the mean difference between groups divided by the pooled standard deviation We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.